Language:
English
繁體中文
Help
Login
Back
Switch To:
Labeled
|
MARC Mode
|
ISBD
Resistance to ibritumomab in lymphoma
~
SpringerLink (Online service)
Resistance to ibritumomab in lymphoma
Record Type:
Language materials, printed : Monograph/item
Title/Author:
Resistance to ibritumomab in lymphoma/ edited by Makoto Hosono, Jean-Francois Chatal.
other author:
Hosono, Makoto.
Published:
Cham :Springer International Publishing : : 2018.,
Description:
xiii, 158 p. :ill., digital ; : 24 cm.;
Contained By:
Springer eBooks
Subject:
Lymphomas - Treatment. -
Online resource:
http://dx.doi.org/10.1007/978-3-319-78238-6
ISBN:
9783319782386
Resistance to ibritumomab in lymphoma
Resistance to ibritumomab in lymphoma
[electronic resource] /edited by Makoto Hosono, Jean-Francois Chatal. - Cham :Springer International Publishing :2018. - xiii, 158 p. :ill., digital ;24 cm. - Resistance to targeted anti-cancer therapeutics,v.182196-5501 ;. - Resistance to targeted anti-cancer therapeutics ;v.4..
Clinical Use and Efficacy of Ibritumomab in B-cell Lymphoma -- Biology and Pathology of B-cell lymphoma -- Resistance to Y-90 Ibritumomab Tiuxetan Therapy -- Features of Ibritumomab as Radionuclide Therapy -- Radiological Evaluation of Response and Resistance of Ibritumomab -- Characteristics of Ibritumomab as Radionuclide Therapy Agent -- Resistance and Heterogeneity of Intratumoral Antibody Distribution -- Radiation Dosimetry in Ibritumomab Therapy -- Combining RAIT and immune-based therapies to overcome resistance in cancer? -- Prospects for enhancing efficacy of radioimmunotherapy -- Index.
This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.
ISBN: 9783319782386
Standard No.: 10.1007/978-3-319-78238-6doiSubjects--Topical Terms:
778114
Lymphomas
--Treatment.
LC Class. No.: RC280.L9 / R475 2018
Dewey Class. No.: 616.99446
Resistance to ibritumomab in lymphoma
LDR
:01953nam a2200325 a 4500
001
925560
003
DE-He213
005
20181105143639.0
006
m d
007
cr nn 008maaau
008
190625s2018 gw s 0 eng d
020
$a
9783319782386
$q
(electronic bk.)
020
$a
9783319782379
$q
(paper)
024
7
$a
10.1007/978-3-319-78238-6
$2
doi
035
$a
978-3-319-78238-6
040
$a
GP
$c
GP
041
0
$a
eng
050
4
$a
RC280.L9
$b
R475 2018
072
7
$a
MJCL
$2
bicssc
072
7
$a
MED062000
$2
bisacsh
082
0 4
$a
616.99446
$2
23
090
$a
RC280.L9
$b
R433 2018
245
0 0
$a
Resistance to ibritumomab in lymphoma
$h
[electronic resource] /
$c
edited by Makoto Hosono, Jean-Francois Chatal.
260
$a
Cham :
$c
2018.
$b
Springer International Publishing :
$b
Imprint: Springer,
300
$a
xiii, 158 p. :
$b
ill., digital ;
$c
24 cm.
490
1
$a
Resistance to targeted anti-cancer therapeutics,
$x
2196-5501 ;
$v
v.18
505
0
$a
Clinical Use and Efficacy of Ibritumomab in B-cell Lymphoma -- Biology and Pathology of B-cell lymphoma -- Resistance to Y-90 Ibritumomab Tiuxetan Therapy -- Features of Ibritumomab as Radionuclide Therapy -- Radiological Evaluation of Response and Resistance of Ibritumomab -- Characteristics of Ibritumomab as Radionuclide Therapy Agent -- Resistance and Heterogeneity of Intratumoral Antibody Distribution -- Radiation Dosimetry in Ibritumomab Therapy -- Combining RAIT and immune-based therapies to overcome resistance in cancer? -- Prospects for enhancing efficacy of radioimmunotherapy -- Index.
520
$a
This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.
650
0
$a
Lymphomas
$x
Treatment.
$3
778114
650
0
$a
Drug resistance in cancer cells.
$3
681914
650
1 4
$a
Biomedicine.
$3
593880
650
2 4
$a
Cancer Research.
$3
668358
700
1
$a
Hosono, Makoto.
$3
1203438
700
1
$a
Chatal, Jean-Francois.
$3
1203439
710
2
$a
SpringerLink (Online service)
$3
593884
773
0
$t
Springer eBooks
830
0
$a
Resistance to targeted anti-cancer therapeutics ;
$v
v.4.
$3
1063064
856
4 0
$u
http://dx.doi.org/10.1007/978-3-319-78238-6
950
$a
Biomedical and Life Sciences (Springer-11642)
based on 0 review(s)
Multimedia
Reviews
Add a review
and share your thoughts with other readers
Export
pickup library
Processing
...
Change password
Login